RESVERATROL AND ITS EFFECTS ON DIABETES MELLITUS

Abstract

Diabetes mellitus is a chronic disease that causes complications as a result of insulin resistance, insulin deficiency or the combination of both. It is a public health problem of great importance all over the world due to its high prevalence and complications. Resveratrol is a biologically active polyphenolic compound and in recent years, it is one of the most studied nutrients. The effects of resveratrol, which is abundant in foods such as grapes, peanuts, red wine, blueberries and cherries on human health have been studied for a long time. Antioxidant, proinflammatory, anti-carcinogen and their protective effects against heart diseases and obesity have been tried to be elucidated in studies conducted in humans and animals so far. In addition, it is thought that resveratrol may have effects on the development and complications of diabetes, which is an important public health problem in the world. It has been shown to a beneficial effect on diabetes by modulating glucose homeostasis, increasing insulin sensitivity, reducing insulin resistance and contributing to the preservation of pancreatic tissue by activating AMPK, estrogen receptors and SIRT, improving mitochondrial dysfunction, inhibiting protein-tyrosine phosphatase expression in human and animal experimental studies. Even though it has several positive health effects, especially on diabetes, resveratrol is toxic and a safe intake dose has not been clarified yet. Therefore, more studies should be carried out to understand its safe/toxic dose. In this review, the effects of resveratrol’s polyphenolic compound on diabetes and glucose metabolism parameters and possible mechanisms of action will be examined.

Keywords

• Diabetes mellitus
• resveratrol
• insulin resistance
• antioxidant

References

1. Arora M. K. & Strange R. N. (1991). Phytoalexin accumulation in groundnuts in response to wounding. Plant Science, 78(2), 157–163.
2. Aydın G. & Erbaş O. (2019). The effects of resveratrol on human health. FNG&Demiroğlu Bilim Tıp Dergisi, 5(4), 193–201.
3. Bay Karabulut, A. (2008). Resveratrol ve etkileri. Turkiye Klinikleri Journal of Medical Sciences, 28(6 SUPPL.), 166–169.
4. Camont L., Cottart C. H., Rhayem Y., Nivet-Antoine V., Djelidi R., Collin F., … Bonnefont-Rousselot, D. (2009). Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. Analytica Chimica Acta, 634(1), 121–128.
5. Catalgol B., Batirel S., Taga Y. & Ozer N. K. (2012). Resveratrol: French paradox revisited. Frontiers in Pharmacology, JUL 2012(3), 1–18.
6. Chang C.-C., Yang M.-H., Tung H.-C., Chang C.-Y., Tsai Y.-L., Huang J.-P., … Hung L.-M. (2014). Resveratrol exhibits differential protective effects on fast- and slow-twitch muscles in streptozotocin-induced diabetic rats. The Chinese Journal of Physiology, 6(1), 60–67.
7. Chang C. C., Chang C. Y., Huang J. P. & Hung L. M. (2012). Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chinese Journal of Physiology, 55(3), 192–201.
8. Chen K. H., Hung C. C., Hsu H. H., Jing Y. H., Yang C. W. & Chen J. K. (2011). Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chemico-Biological Interactions, 190(1), 45–53.

9. Cheng A. Y. Y. & Fantus I. G. (2005). Oral antihyperglycemic therapy for type 2 diabetes mellitus. Canadian Medical Association Journal, 172(2), 213–226.
10. Chi T. C., Chen W. P., Chi T. L., Kuo T. F., Lee S. S., Cheng J. T. & Su M. J. (2007). Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sciences, 80(18), 1713–1720.
11. Côté C. D., Rasmussen B. A., Duca F. A., Zadeh-Tahmasebi M., Baur J. A., Daljeet M., … Lam T. K. T. (2015). Resveratrol activates duodenal Sirt1 to reverse insulin resistance in rats through a neuronal network. Nature Medicine, 21(5), 498–505.
12. Cottart C.-H., Nivet-Antoine V. & Beaudeux J.-L. (2014). Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Molecular Nutrition & Food Research, 58(1), 7–21.
13. Cottart C.-H., Nivet-Antoine V., Laguillier-Morizot C. & Beaudeux, J.-L. (2010). Resveratrol bioavailability and toxicity in humans. Molecular Nutrition & Food Research, 54(1), 7–16.
14. de Ligt M., Timmers S. & Schrauwen P. (2015). Resveratrol and obesity: Can resveratrol relieve metabolic disturbances? Biochimica et Biophysica Acta, 1852(6), 1137–1144.
15. Dixon R. A. (2001). Natural products and plant disease resistance. Nature, 411, 843–847.
16. Elbe H., Vardi N., Esrefoglu M., Ates B., Yologlu S. & Taskapan C. (2015). Amelioration of streptozotocin-induced diabetic nephropathy by melatonin, quercetin, and resveratrol in rats. Human and Experimental Toxicology, 34(1), 100–113.
17. Erkan S. O., Tuhanioğlu B., Gürgen S. G., Özdaş T., Taştekin B., Pelit A. & Görgülü O. (2019). The effect of resveratrol on the histologic characteristics of the cochlea in diabetic rats. Laryngoscope, 129(1), E1–E6.
18. Goh K. P., Lee H. Y., Lau D. P., Supaat W., Chan Y. H. & Koh A. F. Y. (2014). Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. International Journal of Sport Nutrition and Exercise Metabolism, 24(1), 2–13.
19. González-Rodríguez Á., Santamaría B., Mas-Gutierrez J. A., Rada P., Fernández-Millán E., Pardo V., Álvarez C., Cuadrado A., Ros M., Serrano M. & Valverde Á. M. (2015). Resveratrol treatment restores peripheral insulin sensitivity in diabetic mice in a sirt1-independent manner. Molecular Nutrition and Food Research, 59(8), 1431–1442.
20. Huang D. D., Shi G., Jiang Y., Yao C. & Zhu C. (2020). A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomedicine and Pharmacotherapy, 125(November 2019), 109767.
21. International Diabetes Federation (2019). IDF Diabetes Atlas 9th edition. Retrieved from https://www.diabetesatlas.org/en/
22. Jiang B., Guo L., Li B.-Y., Zhen J.-H., Song J., Peng T., … Gao H.-Q. (2013). Resveratrol Attenuates Early Diabetic Nephropathy by Down-Regulating Glutathione S-Transferases Mu in Diabetic Rats. Journal of Medicinal Food, 16(6), 481–486.
23. Jimenez-gomez Y., Mattison J. A., Pearson K. J., Martin-Montalvo A., Palacios H. H., Sossong A. … Tilmont E. M. (2013). Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on a high-fat, high-sugar diet. Cell Metabolism, 18(4), 1–23.
24. Johnson, WD., Morrissey, RL., Usborne, AL., Kapetanovic, I., Crowell, JA., Muzzio, M. & McCormick, DL. (2011). Subchronic oral toxicity and cardiovascular safety pharmacology studies of resveratrol, a naturally occurring polyphenol with cancer preventive activity. Food and Chemical Toxicology. 49(12):3319-27.
25. King R. E., Bomser J. A. & Min D. B. (2006). Bioactivity of Resveratrol. Comprehensive Reviews in Food Science and Food Safety, 5(3), 65–70.
26. Kumar A., Kaundal R. K., Iyer S. & Sharma S. S. (2007). Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sciences, 80(13), 1236–1244.
27. La Porte C., Nha V., Guijun Z., Isabella S., Tardiff D., Singhal N. & William Cameron D. (2010). Steady-State Pharmacokinetics and Tolerability of Trans-Resveratrol 2000 mg Twice Daily with Food, Quercetin and Alcohol (Ethanol) in Healthy Human Subjects. Clinical Pharmacokinetics, 49(7):449-54.
28. Langcake P. & Pryce R. (1977). A new class of phytoalexins from grapevines. EXPERIENTIA, 33(2), 151–152.
29. Lee S. M., Yang H., Tartar D. M., Gao B., Luo X., Ye S. Q., … Fang D. (2011). Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia, 54(5), 1136–1146.
30. Li H., Xia N. & Förstermann U. (2012, February 15). Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide, Vol. 26, pp. 102–110.
31. Liu K., Zhou R., Wang B. & Mi M. T. (2014). Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. American Journal of Clinical Nutrition, 99(6), 1510–1519.
32. Liu X. Q., Wu B. J., Pan W. H. T., Zhang X. M., Liu J. H., Chen M. M., … Chao H. M. (2013). Resveratrol mitigates rat retinal ischemic injury: The roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1. Journal of Ocular Pharmacology and Therapeutics, 29(1), 33–40.
33. Liu Z., Jiang C., Zhang J., Liu B. & Du Q. (2016). Resveratrol inhibits inflammation and ameliorates insulin resistant endothelial dysfunction via regulation of AMP-activated protein kinase and sirtuin 1 activities. Journal of Diabetes, 8(3), 324–335.
34. Luo G., Huang B., Qiu X., Xiao L., Wang N., Gao Q., … Hao L. (2017). Resveratrol attenuates excessive ethanol exposure induced insulin resistance in rats via improving NAD+/NADH ratio. Molecular Nutrition and Food Research, 61(11), 1–11.
35. Maity B., Bora M. & Sur D. (2018). An effect of combination of resveratrol with vitamin D3 on modulation of proinflammatory cytokines in diabetic nephropathy induces rat. Oriental Pharmacy and Experimental Medicine, 18(2), 127–138.
36. Mankowski R. T., You L., Buford T. W., Leeuwenburgh C., Manini T. M., Schneider S., … Anton S. D. (2020). Higher dose of resveratrol elevated cardiovascular disease risk biomarker levels in overweight older adults – A pilot study. Experimental Gerontology, 131, 110821.
37. Mohammadshahi M., Haidari F. & Soufi F. G. (2014). Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress. Cardiology Journal, 21(1), 39–46.
38. Movahed A., Nabipour I., Lieben Louis X., Thandapilly S. J., Yu L., Kalantarhormozi M., … Netticadan T. (2013). Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-Based Complementary and Alternative Medicine, 2013, 1–11.
39. Muñoz O., Muñoz R. & Bustamante, S. (2015). Pharmacological Properties of Resveratrol. A Pre-Clinical and Clinical Review. Biochemistry & Pharmacology: Open Access. 4(5):1-9.
40. Nawaz W., Zhou Z., Deng S., Ma X., Ma X., Li C. & Shu X. (2017). Therapeutic versatility of resveratrol derivatives. Nutrients, 9(11), 1–26.
41. Oyenihi O. R., Oyenihi A. B., Adeyanju A. A. & Oguntibeju O. O. (2016). Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility. Journal of Diabetes Research, 2016(9737483), 1–14.
42. Palsamy P. & Subramanian S. (2009). Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chemico-Biological Interactions, 179(2–3), 356–362.
43. Palsamy P. & Subramanian S. (2010). Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic β-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. Journal of Cellular Physiology, 224(2), 423–432.
44. Pereira S., Park E., Moore J., Faubert B., Breen D. M., Oprescu A. I., … Tsiani E. (2015). Resveratrol prevents insulin resistance caused by short-term elevation of free fatty acids in vivo. Applied Physiology, Nutrition and Metabolism, 40(11), 1129–1136.
45. Pervaiz S. (2003). Resveratrol: from grapevines to mammalian biology. FASEB, 17(14), 1975–1985.
46. Popat R., Plesner T., Davies F., Cook G., Cook M., Elliott P., … Cavenagh J. (2013). A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. British Journal of Haematology, 160(5), 714–717.
47. Poulsen M. M., Vestergaard P. F., Clasen B. F., Radko Y., Christensen L. P., Stødkilde-Jørgensen H., … Jørgensen J. O. L. (2013). High-dose resveratrol supplementation in obese men an investigator- initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 62(4), 1186–1195.
48. Regitz C., Fitzenberger E., Mahn F. L., Dußling L. M. & Wenzel U. (2016). Resveratrol reduces amyloid-beta (Aβ1–42)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans. European Journal of Nutrition, 55(2), 741–747.
49. Sadi G., Ergin V., Yilmaz G., Pektas M. B., Yildirim O. G., Menevse A. & Akar F. (2015). High-fructose corn syrup-induced hepatic dysfunction in rats: improving effect of resveratrol. European Journal of Nutrition, 54(6), 895–904.
50. Salman S., Satman İ., Yılmaz C., İmamoğlu Ş. & Dinççağ N. (2020). TEMD Diabetes Mellitus ve Komplikasyonlarının Tanı, Tedavi ve İzlem Kılavuzu.
51. Shaito A., Posadino A. M., Younes N., Hasan H., Halabi S., Alhababi D., … Pintus, G. (2020). Potential adverse effects of resveratrol: A literature review. International Journal of Molecular Sciences, 21(6), 1–26.
52. Sharma S., Misra C. S., Arumugam S., Roy S., Shah V., Davis J. A., … Ray A. (2011). Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytotherapy Research, 25(1), 67–73.
53. Siemann E. H. & Creasy L. L. (1992). Concentration of the Phytoalexin Resveratrol in Wine. American Journal of Enology and Viticulture, 43(1), 49–52.
54. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X. & Zhai Q. (2007). SIRT1 Improves Insulin Sensitivity under Insulin-Resistant Conditions by Repressing PTP1B. Cell Metabolism, 6(4), 307–319.
55. Szkudelska K. & Szkudelski T. (2010, June 10). Resveratrol, obesity and diabetes. European Journal of Pharmacology, Vol. 635, pp. 1–8.
56. Szkudelski T., & Szkudelska, K. (2015). Resveratrol and diabetes: From animal to human studies. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1852(6), 1145–1154.
57. Thazhath S. S., Wu T., Bound M. J., Checklin H. L., Standfield S., Jones K. L., … Rayner C. K. (2016). Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: A randomized controlled trial. American Journal of Clinical Nutrition, 103(1), 66–70.
58. Tian X., Liu Y., Ren G., Yin L., Liang X., Geng T., … An R. (2016). Resveratrol limits diabetes-associated cognitive decline in rats by preventing oxidative stress and inflammation and modulating hippocampal structural synaptic plasticity. Brain Research, 1650, 1–9.
59. Verspohl E. J. (2012). Novel pharmacological approaches to the treatment of type 2 diabetes. Pharmacological Reviews, 64(2), 188–237.
60. World Health Organization (2021). Diabetes. Retrieved from https://www.who.int/news-room/fact-sheets/detail/diabetes
61. Wong R. H. X. & Howe P. R. C. (2018). Resveratrol counteracts insulin resistance-potential role of the circulation. Nutrients, 10(9), 1–10.